PMID- 29022097
OWN - NLM
STAT- MEDLINE
DCOM- 20180109
LR  - 20210208
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 144
IP  - 1
DP  - 2018 Jan
TI  - Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in 
      squamous cell carcinomas of the head and neck.
PG  - 53-61
LID - 10.1007/s00432-017-2528-x [doi]
AB  - BACKGROUND: FGFR1 is a receptor tyrosine kinases involved in tumor growth 
      signaling, survival, and differentiation in many solid cancer types. There is 
      growing evidence that FGFR1 amplification might predict therapy response to FGFR1 
      inhibitors in squamous cell lung cancers. To estimate the potential applicability 
      of anti FGFR1 therapies in squamous cell carcinomas of the head and neck, we 
      studied patterns of FGFR1 amplification using fluorescence in situ hybridization 
      (FISH). MATERIALS AND METHODS: A tissue microarray was constructed from 453 
      primary treatment-naive squamous cell carcinomas of the head and neck regions 
      with histopathological and clinical follow-up data [including oral cavity 
      (n = 222), oropharynx (n = 126), and larynx (n = 105)]. FGFR1 and centromere 8 
      copy numbers were assessed by dual-color FISH. FGFR1 amplification was defined as 
      a copy number ratio FGFR1: centromere 8 >/= 2.0. HPV sequencing and p16 
      immunohistochemistry (IHC) were applied to FGFR1-amplified cancers. RESULTS: FISH 
      analysis was successful in 297 (66%) of the 453 cancers. FGFR1 amplification was 
      found in 6% of analyzable tumors, and was more frequent in tumors of the oral 
      cavity (13/133 amplified, 10%), than cancers of other localizations (1/79 
      oropharynx, 4/85 larynx; p = 0.007 and 0.159, respectively). One out of 18 FGFR1 
      amplified cancers was HPV positive. No associations were found between FGFR1 
      amplification and tumor phenotype or p16 IHC. CONCLUSIONS: Head and neck cancers 
      are recurrently affected by FGFR1 amplification, with a predominance in cancers 
      of the oral cavity. Finding only one HPV positive and FGFR1 amplified cancer 
      argues against a causal relationship between HPV and FGFR1 amplifications.
FAU - Clauditz, Till Sebastian
AU  - Clauditz TS
AUID- ORCID: 0000-0002-4257-856X
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, 
      Martinistrasse 52, 20246, Hamburg, Germany. t.clauditz@uke.de.
FAU - Bottcher, Arne
AU  - Bottcher A
AD  - Department of Oto-, Rhino, Laryngology, University Medical Center 
      Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
FAU - Hanken, Henning
AU  - Hanken H
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center 
      Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
FAU - Borgmann, Kerstin
AU  - Borgmann K
AD  - Department of Radiation-Oncology, University Medical Center Hamburg-Eppendorf, 
      Martinistrasse 52, 20246, Hamburg, Germany.
FAU - Sauter, Guido
AU  - Sauter G
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, 
      Martinistrasse 52, 20246, Hamburg, Germany.
FAU - Wilczak, Waldemar
AU  - Wilczak W
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, 
      Martinistrasse 52, 20246, Hamburg, Germany.
FAU - Grob, Tobias
AU  - Grob T
AD  - Institute of Pathology, University Bern, Hochschulstrasse 6, 3012, Bern, 
      Switzerland.
FAU - Munscher, Adrian
AU  - Munscher A
AD  - Department of Oto-, Rhino, Laryngology, University Medical Center 
      Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171011
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*enzymology/*genetics/pathology
MH  - Cyclin-Dependent Kinase Inhibitor p16/biosynthesis/genetics
MH  - Female
MH  - Gene Amplification
MH  - Gene Dosage
MH  - Head and Neck Neoplasms/*enzymology/*genetics/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptor, Fibroblast Growth Factor, Type 1/biosynthesis/*genetics
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Tissue Array Analysis
OTO - NOTNLM
OT  - Fibroblastic growth factor receptor 1 (FGFR1)
OT  - Head and neck squamous cell carcinoma (HNSCC)
OT  - Larynx squamous cell carcinoma (LSCC)
OT  - Oral squamous cell carcinoma (OSCC)
OT  - Targeted therapy
EDAT- 2017/10/13 06:00
MHDA- 2018/01/10 06:00
CRDT- 2017/10/13 06:00
PHST- 2017/06/26 00:00 [received]
PHST- 2017/10/03 00:00 [accepted]
PHST- 2017/10/13 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
PHST- 2017/10/13 06:00 [entrez]
AID - 10.1007/s00432-017-2528-x [pii]
AID - 10.1007/s00432-017-2528-x [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2018 Jan;144(1):53-61. doi: 10.1007/s00432-017-2528-x. 
      Epub 2017 Oct 11.